Alnylam Pharmaceuticals (ALNY) Operating Income (QoQ) (2009 - 2026)
Powered by 
Analysis
Alnylam Pharmaceuticals (ALNY) Operating Income (QoQ) (2009 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn |
| 10 | Insmed | 28.06 Bn | 26.90 Bn | 358.27 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -13.85% |
| Mar 31, 2026 | 103.95% |
| Dec 31, 2025 | -64.21% |
| Sep 30, 2025 | 2,371.63% |
| Jun 30, 2025 | -189.61% |
| Mar 31, 2025 | 117.19% |
| Dec 31, 2024 | -36.74% |
| Sep 30, 2024 | -258.20% |
| Jun 30, 2024 | 211.92% |
| Mar 31, 2024 | 62.69% |
| Dec 31, 2023 | -154.43% |
| Sep 30, 2023 | 193.05% |
| Jun 30, 2023 | -53.42% |
| Mar 31, 2023 | 20.57% |
| Dec 31, 2022 | 26.91% |
| Sep 30, 2022 | -34.62% |
| Jun 30, 2022 | -30.64% |
| Mar 31, 2022 | 24.58% |
| Dec 31, 2021 | -7.09% |
| Sep 30, 2021 | -24.30% |